JMKX000623

JMKX000623 is a potent and selective small molecule inhibitor of the voltage-gated sodium channel NaV1.8 (Sodium channel protein type 8 subunit alpha). It was independently developed by Jemincare and is being co-developed with Orion for the treatment of acute and chronic pain conditions, particularly neuropathic pain such as diabetic peripheral neuropathic pain. NaV1.8 plays a pivotal role in modulating the excitability of nociceptive sensory neurons involved in pain transmission from peripheral tissues to the central nervous system. By selectively blocking this channel, JMKX000623 aims to provide non-opioid analgesia without central nervous system side effects or addictive potential. The drug has reached Phase 2 clinical trials for diabetic peripheral neuropathic pain but development was discontinued following risk-benefit analysis based on non-clinical toxicology studies[1][2][4][5][6][7].

Other names

JMKX 000623JMKX000623JMKX-000623ODM 111ODM111ODM-111